INO

Inovio制药
NASDAQ

实时行情|Nasdaq Last Sale

7.74
+0.22
+2.93%
盘后: 7.42 -0.32 -4.13% 19:59 04/03 EDT
开盘
7.31
昨收
7.52
最高
7.94
最低
7.24
成交量
1,105.29万
成交额
--
52周最高
19.36
52周最低
1.915
市值
11.28亿
市盈率(TTM)
-6.4062
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测INO价格均价为10.43,最高价位13.00,最低价为7.00。

EPS

INO 新闻

更多
  • SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS AAN, FLR, INO, MGPI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
  • GlobeNewswire · 3小时前
  • Inovio Pharma down 3% on $150M stock sales deal
  • seekingalpha · 4小时前
  • Cramer's lightning round: Delta Air Lines is not a buy
  • CNBC.com · 7小时前
  • INOVIO ALERT: Kessler Topaz Meltzer & Check, LLP Announces Reminder of Securities Fraud Class Action Lawsuit Filed Against INOVIO PHARMACEUTICALS, INC. - INO
  • ACCESSWIRE · 8小时前

所属板块

生物技术和医学研究
-0.50%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

INO 简况

Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.
展开

微牛提供Inovio Pharmaceuticals Inc(NASDAQ-INO)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的INO股票新闻,以帮助您做出投资决策。